ProciseDxs Near-Patient Diagnostic Platform Gains CE Mark

In vitro diagnostics firm ProciseDx has earned the CE Mark for its point of care rapid diagnostic test platform.

The tests quantify diagnostic and treatment monitoring markers for inflammatory and autoimmune diseases, including celiac, and metabolic syndromes such as diabetes and pre-diabetes.

The near-patient testing platform offers tests that take from two to five minutes. It is slated to be launched in Europe next year, the company said.